Detalhe da pesquisa
1.
Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea.
Sex Transm Infect
; 99(1): 64-69, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36411033
2.
Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants.
Antimicrob Agents Chemother
; 66(1): e0126321, 2022 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34633853
3.
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections.
Antimicrob Agents Chemother
; 66(3): e0149221, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34978887
4.
Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944).
BMC Microbiol
; 21(1): 181, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34130619
5.
Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis).
Antimicrob Agents Chemother
; 64(7)2020 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32284384
6.
A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study.
Antimicrob Agents Chemother
; 64(5)2020 04 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32071044
7.
In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections.
Antimicrob Agents Chemother
; 64(3)2020 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31818823
8.
Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation.
Clin Infect Dis
; 67(4): 504-512, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29617982
9.
Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae.
Antimicrob Agents Chemother
; 62(12)2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30249694
10.
Correction to: Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK2140944).
BMC Microbiol
; 21(1): 293, 2021 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34702186
11.
Clinical assessment of gepotidacin (GSK2140944) as a victim and perpetrator of drug-drug interactions via CYP3A metabolism and transporters.
Clin Transl Sci
; 16(4): 647-661, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36642822
12.
Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants.
Clin Pharmacol Drug Dev
; 12(1): 38-56, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36468634
13.
Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects.
Clin Transl Sci
; 15(9): 2251-2264, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35769034